198 results found.
                
Anika Fully Launches TACTOSET in the U.S.
Anika Therapeutics is commencing full U.S. commercial launch of TACTOSET surgically-delivered therapy for bone repair procedures.
Top 10 Takeaways from Orthopedics in 2019
 
Enabling Technology and Integrated Selling Strategies Drove Orthopedic Growth in the Third Quarter
The third quarter of 2019 brought some standout performances from large players like Stryker, Medtronic, NuVasive and Globus Medical. DePuy Synthes and Zimmer Biomet made incremental progress in returning to market growth. Notably, the top performing players all have well-established enabling tec...
Anika Therapeutics Transforms to Hybrid Commercial Model
Anika Therapeutics reports 3Q19 orthopedic revenue of USD $26.8MM, +11.1% vs. 3Q18.
DePuy Synthes Reports 3Q19 Revenue of $2,137, +1.2% vs. 3Q18
DePuy Synthes reported 3Q19 orthopedic revenue of USD $2,137MM, +1.2% vs. 3Q18.
Orthopedic Public Companies Grow 2.6% YoY in Quarter
By Mike Evers The second quarter of 2019 brought incremental improvement over the first. Year over year revenue grew 2.6% in the quarter for the public companies reported herein compared to 1.1% last quarter. The five largest orthopedic players, which control 58% of the market, showed a...
Anika Launches TACTOSET Bone Repair Therapy
Anika Therapeutics commenced initial U.S. launch of TACTOSET injectable HA-enhanced therapy to treat bone voids and other bone defects of the skeletal system.
Market Insight: Orthobiologic Products Must Become Procedure-Specific
By Andy Carter, Ph.D. Editor’s Note: Orthobiologics play a role in every orthopedic market segment; therefore, the importance of their advancements affects the industry as a whole. We asked Andy Carter, Ph.D., Chief Technology Officer at TheraCell, to give his insight on the ...
Anika Announces First Human Procedure with Injectable Bone Repair Therapy
Anika Therapeutics announced completion of the first human surgical procedure with the company's injectable HA-based therapy to treat bone voids a...
Anika Therapeutics Reports 2Q19 Orthobiologic Revenue of $26.5MM, +1% vs. 2Q18
Anika Therapeutics posts 2Q19 orthobiologic revenue of USD $26.5MM, +1% vs. 2Q18.
Orthopedic Sales in Line with Seasonal Expectations for 1Q19
By Mike Evers The first quarter of 2019 brought modest growth to the orthopedic market, as expected seasonal softness and more competition in digital surgery platforms slowed sales for some of the largest players. The 25 companies listed herein had combined total orthopedic sales of $8....
Anika Therapeutics Reports 1Q19 Orthobiologic Revenue of $21.7MM, +11.6% vs. 1Q18
Anika Therapeutics posts 1Q19 orthobiologic revenue of USD $21.7MM, +11.6% vs. 1Q18.
Revenue Review: 4Q18 and Full Year 2018 Performance Highlights for Public Companies
By Mike Evers Below you’ll find a summary of the major 4Q18 and full year 2018 developments for publicly-traded orthopedic companies. Exhibits 1 and 2 show 4Q18 and full year performance, respectively.  Companies continue to refine their strategies to improve sales mix ...
Anika Therapeutics Reports 4Q18 Orthobiologic Revenue of $23.8MM, -5.3% vs. 4Q17
Anika Therapeutics posts 4Q18 orthobiologic revenue of USD $23.8MM, -5.3% vs. 4Q17, with
Revenue Review: 3Q18 Performance Highlights and 2018 Projections for Public Companies, Continued
By Mike Evers In the exhibits below, we've added nine companies to round out our revenue review for 3Q18. As noted in last month's 
Anika Therapeutics Distributes HA-based Therapies Again
Anika Therapeutics resumed global distribution of HYALOFAST and HYALOGRAFT-C therapies for cartilage repair, following a
3Q18 and 9 Month 2018 Performance Highlights for Public Companies
By Mike Evers Our recap highlights 3Q18 developments and ORTHOWORLD's projection of 2018 full-year revenue for the first publicly traded orthopaedic companies to report. Exhibits 1 and 2 below show year over year company performance for 3Q18 and nine months ending September 30, 2018...
Anika Therapeutics Reports 3Q18 Revenue of $24.1MM, +0.4% vs. 3Q17
Anika Therapeutics posts 3Q18 orthobiologic revenue of $24.1MM, +0.4% vs. 3Q17.
Revenue Review: 1H18 Growth and 2Q18 Performance Highlights for Public Companies
by Julie A. Vetalice The 21 companies tracked below collectively grew +3.6% in 1H18 vs. 1H17, still on track to reach our estimates of +3.7% in orthopaedic industry growth for 2018 vs. 2017. Exhibits 1 and 2 reflect 1H18 results for public orthopaedic companies. The performan...
Anika Therapeutics 2Q18 Orthobiologics Revenue +7% YoY
Anika Therapeutics posted 2Q18 orthobiologic revenue of US $26.2MM, +7.0% vs. 2Q17 and 1H18 revenue of
Public Orthopaedic Companies: 1Q18 Revenue and Growth Drivers
By Julie A. Vetalice The 21 companies tracked in Exhibits 1 and 2 collectively grew +3.1% in 1Q18 vs. 1Q17, remaining on track alongside our estimates of +3.7% in orthopaedic industry growth for 2018 vs. 2017. (Review
Anika Therapeutics Announces Top-Line Results from CINGAL Trial in Knee OA
In the Phase III 16-02 clinical trial of Anika Therapeutics' CINGAL, statistically significant results in pain reduction
Anika Therapeutics Reports 1Q18 Orthobiologic Revenue
Anika Therapeutics posted 1Q18 orthobiologic revenue of US $19.5MM, -3.6% vs. 1Q17.
Public Orthopaedic Companies: 2017 Revenue and 2018 Sales Drivers
By Julie A. Vetalice The 20 companies tracked in Exhibits 1 and 2 collectively grew +3.0% in 2017 vs. 2016. Individually, you’ll notice some stellar performance in particular segments. (Our final estimates for 2017 orthopaedic industry revenue can be found in
Bioventus Launches Durolane in the US
Bioventus commenced U.S. launch of DUROLANE single-injection hyaluronic acid to treat knee OA pain. 
  • ORTHOWORLD INC.
  • 8401 Chagrin Road, Suite 18
  • Chagrin Falls, Ohio 44023 USA
  • Phone: 440.543.2101 • Fax: 440.543.2122
  • ©1992-2019 ORTHOWORLD
  • All Rights Reserved.
  • Site Managed By:
  • Open Professional Group